Dysregulation of glycogen synthase kinase-3β signaling in hepatocellular carcinoma cells

Christèle Desbois-Mouthon, Marie José Blivet-Van Eggelpoël, Eleonore Beurel, Mathieu Boissan, Roland Delélo, Axelle Cadoret, Jacqueline Capeau

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

It has been reported that upstream components of the insulin-like growth factor (IGF) signaling axis could be overexpressed during hepatocarcinogenesis in humans and rodents. However, the signal transduction pathways activated downstream have been poorly studied. Here, we examined whether glycogen synthase kinase-3β (GSK-3β) could be a target in human hepatoma cell lines and transgenic ASV mice with hepatic expression of the SV40 large T antigen. In HuH7, Mahlavu, and Hep3B cells, basal levels of GSK-3βSer9 phosphorylation were strongly elevated, indicating that GSK-3β was inhibited. GSK-3β phosphorylation was insensitive to exogenous IGFs and was blocked with an IGF-1 receptor-neutralizing antibody in Mahlavu and Hep3B cells. By using LY294002 and ML-9, which act as phosphatidylinositol 3-kinase (PI3-K) and Akt inhibitors, respecthvely, we showed that GSK-3β phosphorylation required PI3-K activation in both cell lines whereas downstream Akt activation was required only in Mahlavu cells. However, in the 2 cell lines, GSK-3βSer9 phosphorylation was controlled by protein kinase C (PKC)ζ because it was blocked by an inhibitory PKCζ peptide. The blockage of GSK-3β phosphorylation markedly inhibited glycogen synthesis and decreased β-catenin expression. In addition, the overexpression of a constitutively active GSK-3β reduced AP-1-mediated gene transcription in Hep3B cells. Finally, we observed that reexpression of IGF-2 in tumoral livers from ASV mice was associated with a marked phosphorylation of GSK-3β. In conclusion, our results identify GSK-3β as a molecular target of the constitutive activation of the IGF axis in in vitro and in vivo models of hepatocarcinogenesis. Persistent phosphorylation of GSK-3β could be critical for regulation of glycogen metabolism and cell growth in hepatoma cells.

Original languageEnglish
Pages (from-to)1528-1536
Number of pages9
JournalHepatology
Volume36
Issue number6
DOIs
StatePublished - Dec 1 2002
Externally publishedYes

Fingerprint

Glycogen Synthase Kinase 3
Hepatocellular Carcinoma
Phosphorylation
Somatomedins
Phosphatidylinositol 3-Kinase
Glycogen
Cell Line
Protein Kinase C
Polyomavirus Transforming Antigens
Somatomedin Receptors
Catenins
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
C-Peptide
Liver
Viral Tumor Antigens
Transcription Factor AP-1
Neutralizing Antibodies
Transgenic Mice
Rodentia
Signal Transduction

ASJC Scopus subject areas

  • Hepatology

Cite this

Desbois-Mouthon, C., Blivet-Van Eggelpoël, M. J., Beurel, E., Boissan, M., Delélo, R., Cadoret, A., & Capeau, J. (2002). Dysregulation of glycogen synthase kinase-3β signaling in hepatocellular carcinoma cells. Hepatology, 36(6), 1528-1536. https://doi.org/10.1053/jhep.2002.37192

Dysregulation of glycogen synthase kinase-3β signaling in hepatocellular carcinoma cells. / Desbois-Mouthon, Christèle; Blivet-Van Eggelpoël, Marie José; Beurel, Eleonore; Boissan, Mathieu; Delélo, Roland; Cadoret, Axelle; Capeau, Jacqueline.

In: Hepatology, Vol. 36, No. 6, 01.12.2002, p. 1528-1536.

Research output: Contribution to journalArticle

Desbois-Mouthon, C, Blivet-Van Eggelpoël, MJ, Beurel, E, Boissan, M, Delélo, R, Cadoret, A & Capeau, J 2002, 'Dysregulation of glycogen synthase kinase-3β signaling in hepatocellular carcinoma cells', Hepatology, vol. 36, no. 6, pp. 1528-1536. https://doi.org/10.1053/jhep.2002.37192
Desbois-Mouthon C, Blivet-Van Eggelpoël MJ, Beurel E, Boissan M, Delélo R, Cadoret A et al. Dysregulation of glycogen synthase kinase-3β signaling in hepatocellular carcinoma cells. Hepatology. 2002 Dec 1;36(6):1528-1536. https://doi.org/10.1053/jhep.2002.37192
Desbois-Mouthon, Christèle ; Blivet-Van Eggelpoël, Marie José ; Beurel, Eleonore ; Boissan, Mathieu ; Delélo, Roland ; Cadoret, Axelle ; Capeau, Jacqueline. / Dysregulation of glycogen synthase kinase-3β signaling in hepatocellular carcinoma cells. In: Hepatology. 2002 ; Vol. 36, No. 6. pp. 1528-1536.
@article{f153add58e9a4d0aae5bfbd1c96b730c,
title = "Dysregulation of glycogen synthase kinase-3β signaling in hepatocellular carcinoma cells",
abstract = "It has been reported that upstream components of the insulin-like growth factor (IGF) signaling axis could be overexpressed during hepatocarcinogenesis in humans and rodents. However, the signal transduction pathways activated downstream have been poorly studied. Here, we examined whether glycogen synthase kinase-3β (GSK-3β) could be a target in human hepatoma cell lines and transgenic ASV mice with hepatic expression of the SV40 large T antigen. In HuH7, Mahlavu, and Hep3B cells, basal levels of GSK-3βSer9 phosphorylation were strongly elevated, indicating that GSK-3β was inhibited. GSK-3β phosphorylation was insensitive to exogenous IGFs and was blocked with an IGF-1 receptor-neutralizing antibody in Mahlavu and Hep3B cells. By using LY294002 and ML-9, which act as phosphatidylinositol 3-kinase (PI3-K) and Akt inhibitors, respecthvely, we showed that GSK-3β phosphorylation required PI3-K activation in both cell lines whereas downstream Akt activation was required only in Mahlavu cells. However, in the 2 cell lines, GSK-3βSer9 phosphorylation was controlled by protein kinase C (PKC)ζ because it was blocked by an inhibitory PKCζ peptide. The blockage of GSK-3β phosphorylation markedly inhibited glycogen synthesis and decreased β-catenin expression. In addition, the overexpression of a constitutively active GSK-3β reduced AP-1-mediated gene transcription in Hep3B cells. Finally, we observed that reexpression of IGF-2 in tumoral livers from ASV mice was associated with a marked phosphorylation of GSK-3β. In conclusion, our results identify GSK-3β as a molecular target of the constitutive activation of the IGF axis in in vitro and in vivo models of hepatocarcinogenesis. Persistent phosphorylation of GSK-3β could be critical for regulation of glycogen metabolism and cell growth in hepatoma cells.",
author = "Christ{\`e}le Desbois-Mouthon and {Blivet-Van Eggelpo{\"e}l}, {Marie Jos{\'e}} and Eleonore Beurel and Mathieu Boissan and Roland Del{\'e}lo and Axelle Cadoret and Jacqueline Capeau",
year = "2002",
month = "12",
day = "1",
doi = "10.1053/jhep.2002.37192",
language = "English",
volume = "36",
pages = "1528--1536",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Dysregulation of glycogen synthase kinase-3β signaling in hepatocellular carcinoma cells

AU - Desbois-Mouthon, Christèle

AU - Blivet-Van Eggelpoël, Marie José

AU - Beurel, Eleonore

AU - Boissan, Mathieu

AU - Delélo, Roland

AU - Cadoret, Axelle

AU - Capeau, Jacqueline

PY - 2002/12/1

Y1 - 2002/12/1

N2 - It has been reported that upstream components of the insulin-like growth factor (IGF) signaling axis could be overexpressed during hepatocarcinogenesis in humans and rodents. However, the signal transduction pathways activated downstream have been poorly studied. Here, we examined whether glycogen synthase kinase-3β (GSK-3β) could be a target in human hepatoma cell lines and transgenic ASV mice with hepatic expression of the SV40 large T antigen. In HuH7, Mahlavu, and Hep3B cells, basal levels of GSK-3βSer9 phosphorylation were strongly elevated, indicating that GSK-3β was inhibited. GSK-3β phosphorylation was insensitive to exogenous IGFs and was blocked with an IGF-1 receptor-neutralizing antibody in Mahlavu and Hep3B cells. By using LY294002 and ML-9, which act as phosphatidylinositol 3-kinase (PI3-K) and Akt inhibitors, respecthvely, we showed that GSK-3β phosphorylation required PI3-K activation in both cell lines whereas downstream Akt activation was required only in Mahlavu cells. However, in the 2 cell lines, GSK-3βSer9 phosphorylation was controlled by protein kinase C (PKC)ζ because it was blocked by an inhibitory PKCζ peptide. The blockage of GSK-3β phosphorylation markedly inhibited glycogen synthesis and decreased β-catenin expression. In addition, the overexpression of a constitutively active GSK-3β reduced AP-1-mediated gene transcription in Hep3B cells. Finally, we observed that reexpression of IGF-2 in tumoral livers from ASV mice was associated with a marked phosphorylation of GSK-3β. In conclusion, our results identify GSK-3β as a molecular target of the constitutive activation of the IGF axis in in vitro and in vivo models of hepatocarcinogenesis. Persistent phosphorylation of GSK-3β could be critical for regulation of glycogen metabolism and cell growth in hepatoma cells.

AB - It has been reported that upstream components of the insulin-like growth factor (IGF) signaling axis could be overexpressed during hepatocarcinogenesis in humans and rodents. However, the signal transduction pathways activated downstream have been poorly studied. Here, we examined whether glycogen synthase kinase-3β (GSK-3β) could be a target in human hepatoma cell lines and transgenic ASV mice with hepatic expression of the SV40 large T antigen. In HuH7, Mahlavu, and Hep3B cells, basal levels of GSK-3βSer9 phosphorylation were strongly elevated, indicating that GSK-3β was inhibited. GSK-3β phosphorylation was insensitive to exogenous IGFs and was blocked with an IGF-1 receptor-neutralizing antibody in Mahlavu and Hep3B cells. By using LY294002 and ML-9, which act as phosphatidylinositol 3-kinase (PI3-K) and Akt inhibitors, respecthvely, we showed that GSK-3β phosphorylation required PI3-K activation in both cell lines whereas downstream Akt activation was required only in Mahlavu cells. However, in the 2 cell lines, GSK-3βSer9 phosphorylation was controlled by protein kinase C (PKC)ζ because it was blocked by an inhibitory PKCζ peptide. The blockage of GSK-3β phosphorylation markedly inhibited glycogen synthesis and decreased β-catenin expression. In addition, the overexpression of a constitutively active GSK-3β reduced AP-1-mediated gene transcription in Hep3B cells. Finally, we observed that reexpression of IGF-2 in tumoral livers from ASV mice was associated with a marked phosphorylation of GSK-3β. In conclusion, our results identify GSK-3β as a molecular target of the constitutive activation of the IGF axis in in vitro and in vivo models of hepatocarcinogenesis. Persistent phosphorylation of GSK-3β could be critical for regulation of glycogen metabolism and cell growth in hepatoma cells.

UR - http://www.scopus.com/inward/record.url?scp=0036897230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036897230&partnerID=8YFLogxK

U2 - 10.1053/jhep.2002.37192

DO - 10.1053/jhep.2002.37192

M3 - Article

C2 - 12447879

AN - SCOPUS:0036897230

VL - 36

SP - 1528

EP - 1536

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 6

ER -